vce-004.8 (MultiTarget Pharmaceuticals)
90
Structured Review
MultiTarget Pharmaceuticals
vce-004.8
Vce 004.8, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vce-004%2E8/vce+004+8/10__3390_slash_molecules26113245-125-11-21
Average 90 stars, based on 1 article reviews
Vce 004.8, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vce-004%2E8/vce+004+8/10__3390_slash_molecules26113245-125-11-21
Average 90 stars, based on 1 article reviews
vce-004.8 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
In Vivo:Article Title: Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease Article Snippet: A priori, our expectation was that this hybrid activity may provide VCE-004.8 with some advantages in terms of potency and/or Article Title: EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. Article Snippet: Accepted Manuscript EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis Adela García-Martín, Martín Garrido-Rodríguez, Carmen Navarrete, Carmen del Río, María L. Bellido, Giovanni Appendino, Marco A. Calzado, Eduardo Muñoz PII: S0006-2952(18)30317-4 DOI: https://doi.org/10.1016/j.bcp.2018.07.047 Reference: BCP 13230 To appear in: Biochemical Pharmacology Received Date: 9 June 2018 Accepted Date: 31 July 2018 Please cite this article as: A. García-Martín, M. Garrido-Rodríguez, C. Navarrete, C. del Río, M.L.. Bellido, G. Appendino, M.A.. Calzado, E. Muñoz, EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis, Biochemical Pharmacology (2018), doi: https://doi.org/ 10.1016/j.bcp.2018.07.047 This is a PDF file of an unedited manuscript that has been accepted for publication. Activity Assay:Article Title: Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease Article Snippet: A priori, our expectation was that this hybrid activity may provide VCE-004.8 with some advantages in terms of potency and/or Article Title: EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. Article Snippet: Accepted Manuscript EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis Adela García-Martín, Martín Garrido-Rodríguez, Carmen Navarrete, Carmen del Río, María L. Bellido, Giovanni Appendino, Marco A. Calzado, Eduardo Muñoz PII: S0006-2952(18)30317-4 DOI: https://doi.org/10.1016/j.bcp.2018.07.047 Reference: BCP 13230 To appear in: Biochemical Pharmacology Received Date: 9 June 2018 Accepted Date: 31 July 2018 Please cite this article as: A. García-Martín, M. Garrido-Rodríguez, C. Navarrete, C. del Río, M.L.. Bellido, G. Appendino, M.A.. Calzado, E. Muñoz, EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis, Biochemical Pharmacology (2018), doi: https://doi.org/ 10.1016/j.bcp.2018.07.047 This is a PDF file of an unedited manuscript that has been accepted for publication. Formulation:Article Title: Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease Article Snippet: A priori, our expectation was that this hybrid activity may provide VCE-004.8 with some advantages in terms of potency and/or Article Title: EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis. Article Snippet: Accepted Manuscript EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis Adela García-Martín, Martín Garrido-Rodríguez, Carmen Navarrete, Carmen del Río, María L. Bellido, Giovanni Appendino, Marco A. Calzado, Eduardo Muñoz PII: S0006-2952(18)30317-4 DOI: https://doi.org/10.1016/j.bcp.2018.07.047 Reference: BCP 13230 To appear in: Biochemical Pharmacology Received Date: 9 June 2018 Accepted Date: 31 July 2018 Please cite this article as: A. García-Martín, M. Garrido-Rodríguez, C. Navarrete, C. del Río, M.L.. Bellido, G. Appendino, M.A.. Calzado, E. Muñoz, EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis, Biochemical Pharmacology (2018), doi: https://doi.org/ 10.1016/j.bcp.2018.07.047 This is a PDF file of an unedited manuscript that has been accepted for publication. |